cTACE
cTACE is a pharmaceutical drug with 9 clinical trials. Currently 3 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
2
Early Stage
0
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
0.0%
0 of 1 finished
100.0%
1 ended early
3
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
DEB-TACE vs cTACE in HCC After TIPS
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
Clinical Trials (9)
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
DEB-TACE vs cTACE in HCC After TIPS
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
TACE With Dicycloplatin(TP21) in Unresectable HCC
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9